Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting
November 03 2022 - 9:40AM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage
gene editing company developing ARCUS®-based ex vivo allogeneic CAR
T and in vivo gene editing therapies, today announced that an
abstract on the effective cell dose and functional attributes of
the company’s lead CD19 candidate, Azercabtagene Zapreleucel
(azer-cel) was accepted for poster presentation at the 64th
American Society of Hematology (ASH) Annual Meeting and Exposition,
being held December 10-13, 2022 in New Orleans, Louisiana.
Precision is currently evaluating azer-cel in a Phase 1/2a clinical
trial of adult subjects with relapsed or refractory (R/R)
non-Hodgkin lymphoma (NHL) who relapsed following treatment with an
autologous CAR T.
“We look forward to seeing this data presented at the ASH
meeting and highlighting the differentiated product cellular
attributes including product composition and cell doses that
contribute to optimized efficacy and safety of azer-cel. This is
the first analysis of an allogeneic CD19 CAR T product composition
to demonstrate that strategies to maximize naïve cell phenotype may
lead to improved safety and efficacy of an allogenic CAR T
therapy,” said Alan List, M.D., Chief Medical Officer of Precision
BioSciences.
Poster Presentation
Details:
Title: Effective Cell Dose and Functional Attributes of
Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with
Allogeneic CAR T-Cell Safety and Efficacy in Patients with
Relapsed/Refractory B-Cell Lymphoma First Author: Caron A.
Jacobson, M.D., Dana Farber Cancer Institute Poster Session:
704. Cellular Immunotherapies: Early Phase and Investigational
Therapies: Poster I Abstract #: 2005 Date/Time:
Saturday, December 10, 2022, 5:30 PM – 7: 30 PM ET Location:
Ernest N. Morial Convention Center, Hall D
The abstract accepted for poster presentation is now available
at www.hematology.org.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology
company dedicated to improving life (DTIL) with its novel and
proprietary ARCUS® genome editing platform. ARCUS is a highly
precise and versatile genome editing platform that was designed
with therapeutic safety, delivery, and control in mind. Using
ARCUS, the company’s pipeline consists of multiple ex vivo
“off-the-shelf” CAR T immunotherapy clinical candidates and several
in vivo gene editing candidates designed to cure genetic and
infectious diseases where no adequate treatments exist. For more
information about Precision BioSciences, please visit
www.precisionbiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding the clinical development and expected efficacy
and benefit of our product candidates, benefits of ARCUS and
potential expansion and development using ARCUS, differentiated
product attributes including product composition and cell doses,
optimized efficacy and safety, and strategies to preserve naïve
cell phenotype. In some cases, you can identify forward-looking
statements by terms such as “aim,” “anticipate,” “approach,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look,” “may,” “mission,” “plan,” “possible,”
“potential,” “predict,” “project,” “pursue,” “should,” “target,”
“will,” “would,” or the negative thereof and similar words and
expressions.
Forward-looking statements are based on management’s current
expectations, beliefs and assumptions and on information currently
available to us. Such statements are subject to a number of known
and unknown risks, uncertainties and assumptions, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various important factors,
including, but not limited to: our ability to become profitable;
our ability to procure sufficient funding and requirements under
our current debt instruments and effects of restrictions
thereunder; risks associated with raising additional capital; our
operating expenses and our ability to predict what those expenses
will be; our limited operating history; the success of our programs
and product candidates in which we expend our resources; our
limited ability or inability to assess the safety and efficacy of
our product candidates; our dependence on our ARCUS technology; the
initiation, cost, timing, progress, achievement of milestones and
results of research and development activities, preclinical studies
and clinical trials; public perception about genome editing
technology and its applications; competition in the genome editing,
biopharmaceutical, and biotechnology fields; our or our
collaborators’ ability to identify, develop and commercialize
product candidates; pending and potential liability lawsuits and
penalties against us or our collaborators related to our technology
and our product candidates; the U.S. and foreign regulatory
landscape applicable to our and our collaborators’ development of
product candidates; our or our collaborators’ ability to obtain and
maintain regulatory approval of our product candidates, and any
related restrictions, limitations and/or warnings in the label of
an approved product candidate; our or our collaborators’ ability to
advance product candidates into, and successfully design, implement
and complete, clinical or field trials; potential manufacturing
problems associated with the development or commercialization of
any of our product candidates; our ability to obtain an adequate
supply of T cells from qualified donors; our ability to achieve our
anticipated operating efficiencies at our manufacturing facility;
delays or difficulties in our and our collaborators’ ability to
enroll patients; changes in interim “top-line” and initial data
that we announce or publish; if our product candidates do not work
as intended or cause undesirable side effects; risks associated
with applicable healthcare, data protection, privacy and security
regulations and our compliance therewith; the rate and degree of
market acceptance of any of our product candidates; the success of
our existing collaboration agreements, and our ability to enter
into new collaboration arrangements; our current and future
relationships with and reliance on third parties including
suppliers and manufacturers; our ability to obtain and maintain
intellectual property protection for our technology and any of our
product candidates; potential litigation relating to infringement
or misappropriation of intellectual property rights; our ability to
effectively manage the growth of our operations; our ability to
attract, retain, and motivate key executives and personnel; market
and economic conditions; effects of system failures and security
breaches; effects of natural and manmade disasters, public health
emergencies and other natural catastrophic events; effects of
COVID-19 pandemic and variants thereof, or any pandemic, epidemic
or outbreak of an infectious disease; insurance expenses and
exposure to uninsured liabilities; effects of tax rules; risks
related to ownership of our common stock and other important
factors discussed under the caption “Risk Factors” in our Quarterly
Report on Form 10-Q for the quarterly period ended June 30, 2022,
as any such factors may be updated from time to time in our other
filings with the SEC, including, but not limited to, our Quarterly
Report on Form 10-Q for the quarterly period ended September 30,
2022, to be filed with the SEC, which are accessible on the SEC’s
website at www.sec.gov and the Investors page of our website under
SEC Filings at investor.precisionbiosciences.com.
All forward-looking statements speak only as of the date of this
press release and, except as required by applicable law, we have no
obligation to update or revise any forward-looking statements
contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221103005817/en/
Investor Contact: Alex Kelly Chief Financial Officer
Alex.Kelly@precisionbiosciences.com
Media Contact: Maurissa Messier Senior Director, Corporate
Communications Maurissa.Messier@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Apr 2023 to Apr 2024